In a retrospective study, DAC achieved a 71.4% complete response (CR) rate, and improved OS of p53‐mutant MDS patients to the level of p53‐wild‐type patients.[47] Furthermore, Welch et al. Here, TP53 is linked to myelodysplastic syndrome.